Freeborn Rwere

Dr. Freeborn Rwere

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RURemigio Usai
Remigio Usai
SMStephen Majoni
Stephen Majoni
Freeborn RwereFreeborn Rwere
Freeborn Rwere
Use of medicinal plants and herbs in the treatment and management of diseases, including diabetes mellitus and its complications remains an integral part of African tradition. In Zimbabwe, nearly one million people are living with diabetes mellitus. The prevalence of diabetes mellitus in Zimbabwe is increasing every year due to lifestyle changes, and has accelerated the use of traditional medicines for its treatment and management in urban areas. In addition, the high cost of modern medicine has led many people in rural parts of Zimbabwe to rely on herbal plant medicine for the treatment of diabetes mellitus and its complications. This review highlights a number of studies carried out to evaluate the antidiabetic properties of indigenous plants found in Zimbabwe with the goal of treating diabetes mellitus. Further, we discuss the mechanism of action of various plant extracts in the treatment and management of diabetes mellitus. Together, this review article can open pathways leading to discovery of new plant derived medicines and regularization of use of crude plant remedies to treat diabetes mellitus by the Zimbabwean government and others across Africa.

25 January 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
HGHongchao Guo
Hongchao Guo
XYXuan Yu
Xuan Yu
YLYu Liu
Yu Liu
DPDavid T. Paik
David T. Paik
JJJohanne Marie Justesen
Johanne Marie Justesen
JWJoseph C. Wu
Joseph C. Wu
The common aldehyde dehydrogenase 2 (ALDH2) alcohol flushing variant known asALDH2*2affects ∼8% of the world’s population. Even in heterozygous carriers, this missense variant leads to a severe loss of ALDH2 enzymatic activity and has been linked to an increased risk of coronary artery disease (CAD). Endothelial cell (EC) dysfunction plays a determining role in all stages of CAD pathogenesis, including early-onset CAD. However, the contribution ofALDH2*2to EC dysfunction and its relation to CAD are not fully understood. In a large genome-wide association study (GWAS) from Biobank Japan,ALDH2*2was found to be one of the strongest single-nucleotide polymorphisms associated with CAD. Clinical assessment of endothelial function showed that human participants carryingALDH2*2exhibited impaired vasodilation after light alcohol drinking. Using human induced pluripotent stem cell–derived ECs (iPSC-ECs) and CRISPR-Cas9–correctedALDH2*2iPSC-ECs, we modeledALDH2*2-induced EC dysfunction in vitro, demonstrating an increase in oxidative stress and inflammatory markers and a decrease in nitric oxide (NO) production and tube formation capacity, which was further exacerbated by ethanol exposure. We subsequently found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin mitigatedALDH2*2-associated EC dysfunction. Studies inALDH2*2knock-in mice further demonstrated that empagliflozin attenuatedALDH2*2-mediated vascular dysfunction in vivo. Mechanistically, empagliflozin inhibited Na+/H+-exchanger 1 (NHE-1) and activated AKT kinase and endothelial NO synthase (eNOS) pathways to ameliorateALDH2*2-induced EC dysfunction. Together, our results suggest thatALDH2*2induces EC dysfunction and that SGLT2i may potentially be used as a preventative measure against CAD forALDH2*2carriers.

1 February 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SHShufang He
Shufang He
VZVanessa O Zambelli
Vanessa O Zambelli
PRPritam Sinha Roy
Pritam Sinha Roy
LBLaura Brabenec
Laura Brabenec
YBYang Bian
Yang Bian
EGEric Gross
Eric Gross
Pain signals are relayed to the brain via a nociceptive system, and in rare cases, this nociceptive system contains genetic variants that can limit the pain response. Here, we questioned whether a human transient receptor potential vanilloid 1 (TRPV1) missense variant causes a resistance to noxious stimuli and, further, whether we could target this region with a cell-permeable peptide as a pain therapeutic. Initially using a computational approach, we identified a human K710N TRPV1 missense variant in an otherwise highly conserved region of mammalian TRPV1. After generating a TRPV1K710N-knockin mouse using CRISPR/Cas9, we discovered that the K710N variant reduced capsaicin-induced calcium influx in dorsal root ganglion neurons. The TRPV1K710N rodents also had less acute behavioral responses to noxious chemical stimuli and less hypersensitivity to nerve injury, while their response to noxious heat remained intact. Furthermore, blocking this K710 region in WT rodents using a cell-penetrating peptide limited acute behavioral responses to noxious stimuli and returned pain hypersensitivity induced by nerve injury to baseline levels. These findings identify K710 TRPV1 as a discrete site that is crucial for the control of nociception and provide insights into how to leverage rare genetic variants in humans to uncover fresh strategies for developing pain therapeutics.


24 April 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
BNBrilliant Nyathi
Brilliant Nyathi
JBJonathan Tatenda Bvunzawabaya
Jonathan Tatenda Bvunzawabaya
CMChido Venissa P Mudawarima
Chido Venissa P Mudawarima
EMEmily Manzombe
Emily Manzombe
KTKudakwashe Tsotsoro
Kudakwashe Tsotsoro
Freeborn RwereFreeborn Rwere
Freeborn Rwere

1 November 2021 in South African Journal of Botany
Verified
Journal Article
Open access
MSMajor A. Selemani
Major A. Selemani
LKLuckmore F. Kazingizi
Luckmore F. Kazingizi
EMEmily Manzombe
Emily Manzombe
LBLorraine Y. Bishi
Lorraine Y. Bishi
CMCleopas Mureya
Cleopas Mureya
Freeborn RwereFreeborn Rwere
Freeborn Rwere